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Recombinant adeno-associated virus (rAAV)-based gene ther-
apy has entered a phase of clinical translation and commercial-
ization. Despite this progress, vector integrity following
production is often overlooked. Compromised vectors may
negatively impact therapeutic efﬁcacy and safety. Using single
molecule, real-time (SMRT) sequencing, we can comprehen-
sively proﬁle packaged genomes as a single intact molecule
and directly assess vector integrity without extensive prepara-
tion. We have exploited this methodology to proﬁle all hetero-
geneic populations of self-complementary AAV genomes via
bioinformatics pipelines and have coined this approach AAV-
genome population sequencing (AAV-GPseq). The approach
can reveal the relative distribution of truncated genomes versus
full-length genomes in vector preparations. Preparations that
seemingly show high genome homogeneity by gel electropho-
resis are revealed to consist of less than 50% full-length species.
With AAV-GPseq, we can also detect many reverse-packaged
genomes that encompass sequences originating from plasmid
backbone, as well as sequences from packaging and helper plas-
mids. Finally, we detect host-cell genomic sequences that are
chimeric with inverted terminal repeat (ITR)-containing vector
sequences. We show that vector populations can contain be-
tween 1.3% and 2.3% of this type of undesirable genome. These
discoveries redeﬁne quality control standards for viral vector
preparations and highlight the degree of foreign products in
rAAV-based therapeutic vectors.
INTRODUCTION
Recombinant adeno-associated viruses (rAAVs) have recently
become an attractive delivery vehicle for the expression of therapeutic
gene products. The speciﬁc need for clinical grade vectors for human
application demands rigorous quality control (QC) tests to assess vec-
tor purity and integrity. Unfortunately, current standard QC proto-
cols are primarily limited to the titration and quantiﬁcation of vector
by qPCR analysis, veriﬁcation of genome size by native or alkaline
(denaturing) agarose-gel electrophoresis, and characterization of viral
purity by silver-stained polyacrylamide gel electrophoresis.1 These
methods do not characterize the prevalence, compositions, or struc-
tures of fragmented genomes. Heterogeneous populations composed
of smaller than unit-length genomes were originally observed in wild-
type AAV (wtAAV) as a consequence of abortive replication that
generate a pool of defective interfering (DI) particles.2,3 A handful
of studies have used high-throughput sequencing approaches to pro-
ﬁle packaged single-stranded (ss)AAV genomes to assess the extent of
“error-prone” genome encapsidation during rAAV production.4,5
However, these methods fall short in their ability to interrogate entire
genomes from 50 inverted terminal repeat (ITR) to 30 ITR as a single
intact molecule. There is also a lack of effective and standardized
methodologies for detailing the nature and abundance of erroneously
packaged sequences originating from the host-cell genome of pack-
aging cell lines or viral fragments originating from Ad-helper and
rep/cap constructs, despite more than 10 years of documentation.6
Furthermore, the mechanisms underlying many of these events are
not fully understood.
The need to proﬁle heterogeneic rAAV genome populations has taken
on particular signiﬁcance, since we have recently shown that inclu-
sion of sequences that contain secondary structures in the form of
short-hairpin DNAs promote the generation of truncated packaged
genomes.7 This is especially critical since we demonstrated that
rAAVs designed to deliver short-hairpin RNAs (shRNAs), which
have inherent secondary structure, exhibit a high degree of genome
truncations. A consequence of replication stalling followed by
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strand-switching events,8 truncated genomes predominantly exist as
self-complementary strands with a hairpin loop terminating at one
end.7 At the other end, truncated genomes harbor two ITR free
ends, similar to self-complementary (sc)AAV genomes.9,10 We
deduced that when self-complementary sequences are ligated to a sin-
gle-stranded DNA adaptor loop at the free end, they become circular
single-stranded molecules that are ideal for single molecule, real-time
(SMRT) sequencing.11 This ability allowed us, for the ﬁrst time, to
proﬁle the heterogeneous outcomes of rAAVs carrying shRNA cas-
settes on a single-vector scale.
One of the major advantages of SMRT sequencing over short-read
sequencing platforms is that relatively long DNA fragments
(R500 bp) do not need to be reconstructed from fragments in silico
to determine the composition of the template molecules, allowing for
the interrogation of full-length and truncated vector genomes
together. The approach ensures that only single-afﬁxed polymerases
in each zero-mode waveguide (ZMW) at the bottom of the SMRT
cell are evaluated, thus achieving single-vector resolution. In addition,
SMRT sequencing beneﬁts from the use of a phi29 polymerase deriv-
ative, which exhibits strand-displacement activity, making it the most
favorable platform for efﬁcient processivity through the notoriously
difﬁcult to sequence ITR structure.
Here, we fully explore the utility of direct SMRT sequencing of
vector genome populations, aptly named AAV-genome population
sequencing (AAV-GPseq), to proﬁle rAAVs prepared by the
HEK293 cell-triple transfection method.1 Self-complementary
genomes were speciﬁcally proﬁled to demonstrate the diverse applica-
tions of AAV-GPseq. We show that the introduction of an enzyme-
digested Lambda-phage DNA (lDNA) spike-in can normalize read
counts by length to overcome SMRT sequencing molecular loading
bias and to accurately assess the relative abundance of truncated
genome populations. Using AAV-GPseq, we also detect encapsidated,
DNaseI-resistant bacterial sequences originating from reverse pack-
aging events, as well as detection of adenoviral helper and Rep/
Cap-construct sequences packaged into virions. This approach was
also able to identify sequences originating from the host-cell genome.
Importantly, we show that many of these undesired sequences are
chimeric with vector-ITR sequences. Finally, the molecular character-
ization and quantitation of error-prone rAAV genome replication
and packaging events is now possible with AAV-GPseq and can be
easily adapted for research-grade and clinical vector manufacturing
QC pipelines.
RESULTS
AAV-GPseq Can Interrogate Full-Vector scAAV Genome
Sequences from ITR-to-ITR with Single-Vector Genome
Resolution
To test whether SMRT sequencing can be performed on individual
vector molecules as an unbroken strand from ITR-to-ITR, we proﬁled
three scAAV genomes (Figure 1A). The ﬁrst is a conventional scAAV
Figure 1. Single-Particle Resolution Profiling of scAAV Genomes by AAV-Gpseq
(A) Diagrams of scAAV genomes: scAAV-EGFP, scAAV-siFFLuc, and scAAV-shApoB-R. (B) Purified scAAV genomes were subjected to SMRT library preparation by single-
adaptering to SMRTbell adapters (green). The loops opposite the ITRs represent either the mITRs or shDNAs that form the terminal loop. Plus (+) andminus () strands of the
molecule are depicted in red and blue, respectively. Single molecule, real-time sequencing is achieved by strand-displacement polymerase activity, generating linear
consensus reads. Each read therefore reflects the intact scAAV molecule from 50 ITR to 30 ITR.
www.moleculartherapy.org
Molecular Therapy: Methods & Clinical Development Vol. 9 June 2018 131
vector harboring the EGFP transgene driven by the chicken-b-actin/
CMV promoter (scAAV-EGFP). The second and third are similar to
scAAV-EGFP but contain shRNA cassettes designed to knock down
the expression of either the ﬁreﬂy luciferase (FFLuc) gene or the
Apolipoprotein B (ApoB) gene (scAAV-siFFLuc and scAAV-
shApoB-R, respectively). To interrogate scAAV vector genome pop-
ulations, virions were proteolyzed to release genomes. Following
DNA nick and end repair, vectors were directly ligated to SMRTbell
adaptor at the open end of the molecule, generating a circular single-
strand DNA template library ideal for SMRT sequencing. Libraries
were loaded onto SMRT cells by diffusion and subjected to standard
Pacbio real-time sequencing (Figure 1B; see Materials and Methods).
The resulting high-quality linear-consensus sequences that passed
CCS2-deﬁned quality scoring (Table 1) were aligned to the appro-
priate custom reference sequences reﬂecting a single-stranded linear-
ized molecule stretching from the 50 ITR to the 30 ITR, with the
mutant ITR (mITR) at the center of the sequence (Figure 2A).
Upon visualizing only fully aligned reads, we immediately noticed
that the abundance of full-length reads was much lower for
vectors harboring shRNA cassettes (scAAV-siFFLuc and scAAV-
shApoB-R) (Figure 2B). This outcome is in agreement with our
previous ﬁnding that inclusion of short hairpin DNA (shDNA) se-
quences result in the generation of shorter than unit-length molecules
and a reduction in full-length molecules as a consequence.7 We also
noticed that sequences align in the forward or reverse orientations
at near 1:1 ratios (Figure 2B, red and blue aligned reads, respectively).
This observation coincides with previous ﬁndings that plus (+)
stranded and minus () stranded genomes are packaged into capsids
at equal ratios.12 Even more striking is the ability to detect the distri-
bution of ITR ﬂip and ﬂop orientations.13 Several studies have shown
that ITR orientations are established during genome replication and
that ITR ﬂip/ﬂop conﬁgurations are established independently of
each other.14,15 Replication models for wtAAV suggest that over
several rounds of replication, the four possible conﬁgurations: ﬂip/
ﬂip, ﬂip/ﬂop, ﬂop/ﬂip, and ﬂop/ﬂop reach a 1:1:1:1 steady-state
ratio.16 For the ﬁrst time, AAV-GPseq enables us to directly identify
and quantitate the distribution of packaged plus/minus strands and
ﬂip/ﬂop conﬁgurations in rAAV preparations. Interestingly, we
observed that ratios for ﬂip/ﬂop distribution for all three scAAV vec-
tors are closer to 2.3:1:1:2.3 (Figure 2C). Based on a simpliﬁed rolling
hairpin replication model as described by Cotmore and Tattersall,17
we have predicted the replication outcomes for 15 generations start-
ing from a single plasmid by computational modeling (Figures S1
and S2). We speculate that since ITR resolution and replication
cannot initiate at the mITR, the distribution is shifted toward ﬂip/
ﬂip and ﬂop/ﬂop conﬁgurations. Interestingly, this model predicts
that the steady-state levels of ﬂip/ﬂop conﬁgurations are 2:1:1:2,
only slightly different from our observed distribution (Figure S2G).
It is plausible that only a few replication rounds occur after plasmid
rescue, resulting in this difference. The model also predicts that
strandness (plus/minus) ratios for each ﬂip/ﬂop conﬁguration do
not reach 1:1 until the 10th generation (Figure S2H). The observation
that the plus/minus ratios deviate from 1.00 for the majority of ﬂip/
ﬂop conﬁgurations in our test vectors certainly support this notion.
However, the sample size here may be too low to reach any deﬁnitive
conclusions.
AAV-GPseq Can Assess the Relative Abundances of
Heterogeneous Populations of Vector Genomes
Initial analyses of scAAV-EGFP, scAAV-siFFLuc, and scAAV-
shApoB-R vectors by sequence length showed a weak correlation
to what we observed of heterogeneous genomes as detected by
ethidium bromide (EtBr)-stained agarose-gels (Figure 3). Strikingly,
the majority of reads were overrepresented by species with lengths
that were less than 500 bp. The discrepancy between agarose-gel an-
alyses and read distribution by SMRT sequencing was somewhat
anticipated based on our previous work that showed SMRT cell
loading led to size-representation bias.7 To overcome any possible
discrepancy, we reasoned that DNA fragments of known lengths
can be used as spike-ins to normalize for abundance differences to
obtain a much more accurate assessment of heterogeneic population
representation. For each vector genome preparation, we supple-
mented each sample with 10% (by mass) BstEII digested lDNA.
Read-length proﬁles of diffusion loaded lDNA reveals a heavy bias
toward the representation of smaller molecules (Figure S3), with
the frequency of detection decaying exponentially as fragment
lengths increase. By ﬁtting these values to a polynomial-spline as a
normalization function, we transformed observed read lengths by
their expected abundances to yield adjusted abundance values (Fig-
ures S3B–S3D). Following abundance transformation, traces for all
three of the vector genome populations now correlate more with
their respective agarose-gel results (Figure 3, right panels). More
importantly, we are now able to calculate the relative abundances
of full-length molecules versus truncated species. By stacking dia-
grams of the appropriate vector genome over their respective abun-
dance trace, we may also predict the hotspots for intramolecular
strand-switching events,7 which give rise to these truncated species
(Figure 3, right panels). Surprisingly, even though agarose-gel anal-
ysis indicated that the scAAV-EGFP full-length species (2.1-kb
band) is the predominant packaged vector (Figure 3A), analysis by
AAV-GPseq suggests that the 2.1-kb molecular form only makes
up 45.39% of all vector-mapped reads. Similarly, scAAV-siFFLuc
and scAAV-shApoB-R vectors also resulted in an extremely low
percentage of full-length species (7.55% and 11.91%, respectively)
(Figures 3B and 3C). This unexpectedly low abundance of full-length
forms compared to agarose-gel assessments is attributed to the strik-
ingly high abundance of reads that were below 500 bp in length and
were not visible by EtBr staining.
Table 1. Percentage of Chimeras in Heterogeneous Genome Populations
Post-normalization of Reads
Construct
Hg38 (Human
Genome)
pAdDeltaF6 (Helper
Plasmid)
pAAV2-9 (Packaging
Plasmid)
scAAV-EGFP 1.32% 1.98% 1.52%
scAAV-siFFLuc 1.77% 0.23% 0.65%
scAAV-shApoB-R 2.31% 2.73% 2.12%
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AAV-GPseq Reveals Vector Populations Carrying Plasmid
Backbone Sequences
We next assessed the coverage of the reads across the vector plasmid
to evaluate the ability of SMRT sequencing to detect packaging of ge-
nomes encompassing regions beyond the ITRs (i.e., plasmid back-
bone sequences).18 Since each scAAV molecule is actually a linear
self-complementary sequence with two ITRs at the open ends of
the vector genome, only one-half of the molecule will properly align
to a vector reference, while the other complementary strand should
not. To demonstrate this effect, alignments were displayed on the
Integrative Genome Viewer (IGV) browser to include the segments
of the reads that do not align to the reference, also known as “soft-
clipped” bases (Figure 4A–4C, colored portions of alignments).19
In addition, visualizing alignments on a circular plasmid reference
conﬁrmed that a minority population of reads indeed encompass
sequences ranging beyond the mITR and wild-type ITR (wtITR) re-
gions for all three test vector genomes (Figures 4D–4F). We attrib-
uted the origins of these species to reversed-packaged genomes6 or
from larger-than-unit-length molecules that package sequences
beyond the mITR.20 We also conﬁrmed that the shorter-than-full-
length sequences from scAAV-siFFLuc and scAAV-shApoB-R vec-
tor preparations shown in Figures 3B and 3C indeed map from the
wtITR region to the shDNA sequences (Figures 4B and 4C). Finally,
we observed that the majority of truncated genomes with sizes under
500 bp in length also span the wtITR region (i.e., gray segments of
the linear alignments all overlap with the wtITR sequence) (Figures
4A–4C). This latter ﬁnding initially suggested that vectors containing
only AAV ITRs could be packaged into capsids. However, we ques-
tioned whether this interpretation was accurate. Fragment analysis of
puriﬁed vector genomes by capillary electrophoresis demonstrates
that the small molecular weight species, which are under 500 bp,
are at background levels of detection or non-existent for all vectors
tested (Figure S4). Although SMRT sequencing relies on the
strand-displacing polymerase derived from phi29, which should be
processive through sequences with high secondary structures, we
aimed to assess whether replication error during SMRT sequencing
Figure 2. Reads from SMRT Sequencing Yield Full-Length Vector Genomes from 50 ITR to 30 ITR
(A) Diagram of a generic scAAV genome depicted as an intramolecular double-strandedmolecule (top) and a single-stranded linear molecule (bottom). (B) Reads of the three
test vectors were aligned to a custom reference sequence as a linear molecule where both “forward” and “reverse” strands are connected by the mITR sequence. Reads are
grouped by strandness (forward, red; reverse, blue) and reflect plus (+) and minus () strand packaging. Alignment summaries are depicted above the read alignments.
Alignment positions that differ from consensus by a frequency of more than 0.05 are highlighted. Here, only the ITRs exhibit significant differences and reflect flip and flop
orientations. The highest frequency of sequencing errors inherent to SMRT sequencing are single-base deletions at poly(G) or poly(C) nucleotides and are marked in IGV as
black dashes and show up as speckles in this collapsed display. (C) Pie charts displaying the distribution of flip and flop vector combinations. Read counts and the plus-to-
minus strand ratios are displayed for each flip/flop configuration.
www.moleculartherapy.org
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can account for the high abundance of short reads identiﬁed by
AAV-GPseq.
We digested our three vector plasmid constructs with PacI, which
cuts directly outside of the mITR and wtITR sequences, and subjected
gel-puriﬁed, ITR-bearing restriction fragments to the AAV-GPseq
pipeline. Strikingly, many of the reads recovered from this analysis
were less than 500 bp in length and speciﬁcally mapped to either
the mITR or the wtITR regions (Figure S5). This unexpected result
indicated that there is some inherent error associated with SMRT
sequencing when it encounters AAV-ITR sequences. At this time, it
is not clear whether these reads are produced from intramolecular
strand-switching events during sequencing or whether they originate
from fragmented material during library preparation steps. Regard-
less, these data suggest that AAV-GPseq cannot accurately interro-
gate encapsidated vector genomes that are smaller than 500 bp, due
to the high frequency of truncated reads at ITR sequences generated
by the technique itself. These data demonstrate that the operational
molecular range for AAV-GPseq to proﬁle heterogeneous scAAV
genome populations is between 2.4 kb and 0.5 kb, where 2.4 kb is
the maximum packaging size for self-complementary vectors.
AAV-GPseq Detects Packaging of Non-vector Genome
Sequences
The packaging of non-vector genomes has long been shown to
occur in rAAV preparations.6 We therefore asked whether AAV-
GPseq could also be tailored to identify and quantitate the abun-
dance of particles packaged with non-vector genome sequences.
We ﬁrst addressed whether any reads were associated with host-
cell genomic sequence. Since the triple-transfection procedures for
rAAV packaging were carried out in HEK239 cells, reads were
mapped to the human genome (hg38 build) to assess host-cell
genomic sequence encapsidation (Figure 5). Indeed, a relatively
high percentage of reads mapped to the hg38 genome (scAAV-
EGFP, 7.19%; scAAV-siFFLuc, 2.76%; and scAAV-shApoB-R,
5.12%). Evaluation of read distribution across the human genome
did not reveal any clear trends for speciﬁc chromosomes. The
only general trend observed for all three vector-preparations
was that the largest chromosome (chr1) exhibited the highest
frequency of mapped reads, while shorter chromosomes tended
to have less mapped reads, suggesting at a more randomized
distribution of host-cell genomic packaging across the genome
(Figure 5A).
Figure 3. Abundance Assessment of Heterogeneous AAV Genome Populations
(A–C) Relative counts of SMRT sequencing reads of (A) scAAV-EGFP, (B) scAAV-siFFLuc, and (C) scAAV-shApoB-R vectors distributed by length/2 (both forward and reverse
strands are sequenced for single-adaptered scAAV genomes). Each vector preparation is accompanied with EtBr-stained agarose gels to demonstrate the distribution of
visually detectable heterogeneous vector genomes. Traces indicate the distribution of truncated genomes before (blue) and after (red) normalization to BstEII-digested lDNA
spike-ins. Traces are scaled to the highest peak set to 100 for ease of comparison. Each trace is aligned to their respective to-scale vector genome diagram from mITR to
wtITR (30 ITR). Normalized read abundances for major peaks are also displayed as a percentage of all reads.
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We next explored the abundance of reads associated with the Ad-
helper plasmid or the AAV2/9 packaging plasmid. Since both of these
plasmids are derived from a Bluescript backbone, and share sequence
similarities to the pCis plasmid, there is no way to discern whether se-
quences containing these aspects originate from the pCis plasmid se-
quences in cis, or from the Ad-helper or AAV2/9 packaging plasmid
constructs in trans. We therefore masked these common sequences
from this analysis. Nonetheless, many reads indeed mapped to the
other plasmid constructs with varying degrees between vector prepa-
rations (Figures 5B and 5C).
Detection and Characterization of Chimeric Reads
We were initially cautious to conclude that all sequences detected by
AAV-GPseq were truly encapsidated. Despite extensive benzonase
nuclease treatment during rAAV puriﬁcation process followed by
DNaseI treatment before extraction of viral DNAs, we still could
not rule out contaminating DNAs as sources of packaged non-vector
sequences. However, it is important to note that vector genome pack-
aging relies on the recognition of the Rep binding element (RBE)
within AAV-ITRs. Furthermore, the passive packaging of random se-
quences into AAV has yet to be formally proven. There are therefore
two possible explanations for encapsidation of non-vector sequences:
(1) contaminating sequences detected by AAV-GPseq have RBE-like
motifs, or (2) vector genomes have recombined with host genomic se-
quences to yield chimeric vector genomes. Upon investigating these
two possibilities, we discovered that a large portion of sequences map-
ping to hg38 also mapped to the vector genome. This ﬁnding revealed
a class of chimeric genomes packaged into rAAV particles. Impor-
tantly, these chimeric sequences all contain ITR sequence (Figure S6),
supporting the hypothesis that host-genomic sequences can be
Figure 4. Alignments of Heterogeneous Vector Populations to the pCis-Plasmid Reference
(A–C) IGV displays illustrating the linear alignments of (A) scAAV-EGFP, (B) scAAV-siFFLuc, and (C) scAAV-shApoB-R vectors across their respective pCis-plasmid refer-
ences. Alignments are displayed with soft-clipped bases toggled on to demonstrate that each self-complementary molecule should align half of its genome to the reference
(gray), while the remaining half should not (colored segments). Alignments are displayed with a 40-read maximum read count per 50-bp window size downsampling. (D–F)
Circos plots of scAAV-EGFP (D), scAAV-siFFLuc (E), and scAAV-shApoB-R (F) vectors demonstrate the coverage of reads across a circular plasmid. The relative thickness of
the track radius (red) directly reflects coverage of reads across the plasmid reference (log-scale). Regions expected to be packaged into AAV capsids are denoted by blue
bars (linear alignments) and blue arch (circus plots). Alignments beyond these regions are referred to as non-vector sequences.
www.moleculartherapy.org
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Figure 5. Detection of Encapsidated Non-vector Genomes
(A) Alignment of SMRT sequence reads for each test vector preparation to the human reference genome (hg38). Venn diagrams display the number of reads mapping to the
vector genome (white circles) and to the human genome (gray circles). Histograms display the abundance of uniquely mapped sites on each chromosome (gray bars) and the
abundance of unique sites that are mapped by reads that also contain vector genome sequences (chimeras, black bars). (B) Alignment data of reads mapping to the Ad-
helper plasmid and (C) to the AAV-Rep/Cap plasmid (note: the conventional AAV2/9 construct contains the p5 TATA-less promoter placed downstream of the Rep/Cap
(legend continued on next page)
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packaged into capsids via recognition of RBE sequences gained by re-
combining with ITR sequences during production. To accurately
assess the abundance of these chimeric reads among the vector ge-
nomes, we normalized these reads to the lDNA spike-in as described
above. After normalization, the percentages of chimeras were calcu-
lated as scAAV-EGFP, 1.32%; scAAV-siFFLuc, 1.77%; and scAAV-
shApoB-R, 2.31% (Table 1). Furthermore, many vector genomes
mapping to the Ad-helper and the packaging plasmid constructs
also appeared to be chimeric genomes (Figures 5B and 5C; Table 1).
Surprisingly, we observed that chimeric sequences did not map
randomly to construct regions. Instead, they are enriched at transgene
promoter sequences (Figures 5B, E4 promoter region, and Figure 5C,
p5 promoter region). These read enrichments suggest that chimeric
reads are a result of vector genomes recombining to sequences that
favor gene promoter regions.
As stated above, chimeric genomes described here are of biological
importance, since they contain intact ITR sequences and present a
means to be packaged into AAV capsids and transduced into cells
in vivo. Furthermore, with intact ITRs, these non-vector sequences
can be reconﬁgured to form stabilized circular molecules, which
can persist in non-dividing cells. We therefore aimed to leverage
the advantage of AAV-GPseq to assess intact vector genome se-
quences to characterize the composition of individual chimeric mol-
ecules. Whenmapped to the human genome, we immediately noticed
that many reads aligned twice to the same regions (Figures S8A and
S8B). For example, of the 13 chimeric reads that map to chromosome
16, six chimeras map twice and one chimera maps four times to the
same genomic position. Analyses of reads attributed to chimeric
species, as well as those that exclusively map to the human genome,
indicate that foreign DNA can be packaged as self-complementary se-
quences that are similar to the conﬁgurations of scAAVs (Figures 5D,
5E, S8D–S8I, and S9). Furthermore, these chimeras display a diversity
of forms. For example, Figure S8H depicts a vector genome that is a
product of six recombination events, incorporating two separate hu-
man genomic sequences and four different regions of packaging
plasmid sequences. Although this is an unprecedented display of
recombination for packaged vectors, only 7.48% of chimeric reads
exhibit multiple recombination events between different genomic
sources (Figure S8J).
Chimeric Host-Cell Genomic Reads Enrich at Promoter
Sequences
The relatively high percentage of ITR-bearing vectors that are
chimeric with host-genomic sequences signiﬁes a potential cause
for concern, since vectors encapsidating genomic sequences of the
host-packaging cell could lead to unanticipated issues. To further
investigate the host-genomic sequences that are being packaged, we
assessed whether these chimeric reads map to gene regions or non-
genic (intergenic) regions (Figure 6). We found that for all three
rAAV preparations, more than 50% of host-cell chimeric reads
map to gene bodies ±2 kb. In the case of scAAV-CB6-EGFP
construct, 60.6% of the chimeric reads map to or within the proximity
of genes.
In Figure 5, we demonstrated that chimeric sequences that capture
packaging vectors tended to map to promoter regions of the adeno-
viral helper and Rep genes. We therefore speculated whether this
feature was also true for chimeras containing host-cell genomic se-
quences. All reads that mapped to hg38 were ﬁrst aggregated and
plotted in a 4-kb window (±2 kb) surrounding transcriptional start
sites (TSSs) or transcriptional end sites (TESs) (Figure 6A). Despite
the low representation of reads mapping to hg38, we noticed that
in all three cases, reads mapping to the TSS or the TES exhibited pe-
riodic aggregation patterns across the deﬁned genomic range. This
pattern is similar in nature to the periodic positioning of nucleosomes
detected at promoters by ChIP-seq analysis or by micrococcal
nuclease (MNase) hypersensitivity.21 Although, the difference here
is that the periodic spacing is far greater, with 500 bp per interval.
When chimeric molecules containing ITR sequences were speciﬁcally
assessed, we found that the combined chimeric reads from all vector
preparations show a signiﬁcant peak of reads aggregating at the TSS,
while the TES lacked any signiﬁcant peaks (Figure 6B). This data sug-
gests that host-cell genome vector chimeras also tend to be associated
with promoter regions.
DISCUSSION
Clinical rAAV efﬁcacy and safety have become crucial focal points
for vector design considerations. To date, the ability to assess vector
genome integrity of encapsidated DNA for clinical and basic
research has mainly relied on agarose-gel electrophoresis, Southern
blot analysis, and PCR techniques. These methods fall short since
they cannot decipher the composition of individual vector genomes,
making in-depth proﬁling of heterogeneous populations difﬁcult.
This type of precise characterization is critical, since it has long
been known that wtAAVs package DI particles.2,3 It has been hy-
pothesized that these DI particles increase viral ﬁtness by eliciting
immune-response with inert virions in the host to favor survival
of the host species and hence perpetuation of the virus.22 This attri-
bute may have translated into undesirable rAAV vector populations
consisting of truncated and/or chimeric genomes. The rAAV-gene
therapy ﬁeld is in need of new techniques that not only detect
the encapsidation of undesirable genomes but can also offer clues
to improve vector homogeneity. Although not all designs that
lead to truncated genomes necessarily compromise transgene
expression,7 the increasing interest of rAAV vectors for clinical
coding sequence). Venn diagrams again display reads mapping to the vector genome (white) and to either the Ad-helper or AAV-rep/cap plasmids (gray). Right, IGV displays
showing individual read alignments to their respective references diagrammed above as a linear strand. Reads mapping in the forward and reverse orientations are indicated
in red and blue, respectively. Reads mapping uniquely to vector backbones were masked, since common sequences between the pCis, Ad-helper (pAdDeltaF6), and Rep-
Cap (pAAV2/9) plasmids cannot be differentiated from each other. (D) Selected hg38-vector chimeric read (121468) showing recombination between the BGH poly(A) of the
vector genome and host-cell sequence mapping to chr16. (E) mFold display of the selected read demonstrating molecular self-complementation.
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applications still necessitates a gold standard for assessing the uni-
formity of gene therapy vector products.
Reliable use of qPCR analysis to proﬁle encapsidated scAAV ge-
nomes have shown that they can exhibit as much as 26% of virions
containing backbone plasmid sequences.20 However, these ap-
proaches only address limited aspects of rAAV heterogeneity. Until
recently, methods to easily quantitate the frequency of erroneously
packaged genomes were not practical for implementation into QC
pipelines. Platforms such as Helicos Biosciences single-molecule
sequencing (SMS) and Illumina-based deep sequencing were
developed to determine the prevalence of less-than-full-length
molecules and the extent of reverse packaging for ssAAVs, respec-
tively.4,5 Unfortunately, these high-throughput methods also fall
short of capturing fully intact vector sequences. The capacity of
AAV-GPseq to be processive through ITR structures is a major
advantage over previous platforms and has allowed for the ﬁrst
time the means to proﬁle vector heterogeneity with full-vector
genome resolution.
With AAV-GPseq, we have shown that certain reads that map to non-
vector sequences are chimeric to vector genomes with intact ITR se-
quences. This is a striking ﬁnding, since chimeric sequences have the
means to actively package into capsids by binding Rep, conﬁrming
that some particles containing non-vector sequences are not a conse-
quence of passive packaging of fragmented DNAs or packaging of
DNAs with RBE-like sequences. This new ﬁnding may be a cause
for concern since packaging of host-genome, rep/cap, or Ad-helper
sequences may result in toxicity for transduced cells. This fear is less-
ened by our ﬁnding that the majority of non-vector sequences are on
average 500 bp in size or smaller, and reads encompassing entire
genes (host-cell, Ad-helper, AAV-rep/cap, or bacterial genes) were
not detected. However, we know that sequence coverage is biased to-
ward smaller molecules. Read abundances after lDNA normalization
Figure 6. Chimeric Reads Are Associated with Promoter Sequences
(A) Distribution of AAV-GPseq reads that map to hg38. Pie charts displaying reads distributed by their association with gene bodies ±2 kb (cyan) or intergenic regions of the
genome (magenta). Aggregation plots show the distribution of reads that map within ±2 kb of transcriptional start sites (TSS) or transcriptional end sites (TES) of all annotated
genes (Refseq annotations). (B) Due to the low abundance of chimeric AAV-GPseq reads, data for all three vectors were combined and subjected to read aggregation
analysis at the TSS and TES of genes. Traces represent the mean read counts per million mapped reads. Shaded areas represent ±SD.
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suggests that longer chimeric reads may be underrepresented
(Figure S7A). Thus, full representation of particles that are chimeric
and package longer fragments of DNAs is a limitation for
AAV-GPseq.
Our study revealed that chimeric sequences tend to map to promoter
sequences. We have hypothesized that short-hairpin structures in
vectors may promote replication stalling.7 In turn, intramolecular-
strand switching may occur as a consequence. Coincidently, similar
stalling events at replication fork barriers (RFBs) within promoter se-
quences are both features of prokaryotic and eukaryotic genomes23
and are known hotspots for recombination. It is plausible that repli-
cation stalling at host-cell promoter regions and rAAV genomes may
promote recombination by intermolecular strand switching, leading
to the production of chimeric vector sequences. Unfortunately, we
did not observe any clear motifs that may drive the formation of
chimeric genomes, nor were there commonalities that deﬁned the
packaging of foreign DNAs that lack ITR elements. Further explora-
tion into these phenomena is crucial for understanding AAV biology
as well as the safety of rAAV for clinical use.
We also note it is more than possible that additional genomic species
are not detected by AAV-GPseq, since the SMRT sequencing meth-
odology may limit full representation of rAAV genomes that are en-
capsidated into rAAV particles. Notably, we have yet to overcome the
inability to quantitate the packaging of vector genomes under 500 bp
in size, since we discovered that subjecting linearized cis-plasmid
DNA to SMRT sequencing resulted in the overrepresentation of
shortened reads that overlapped ITRs (Figure S5). Incidentally, previ-
ous proﬁling of ssAAV genomes by SMS suggested that capsids can be
packaged with DI particles that contain only ITR sequences.4 Initial
interpretation of our own data seemed to lend support for these
genome species. However, we concluded that many of these smaller
read fragments might be artifacts of the sequencing strategy. In reﬂec-
tion, the high thermostability of ITRs may also have impacted SMS
analyses of ssAAVs, since coverage of 50 ends of genomes requires
in vitro extension of viral genomes with DNA polymerase.4
Other possible considerations to take note of when accounting for
non-represented genome species are the populations of genomes
that fail to properly ligate to a SMRTbell adaptor. Whether the
inherent structure of scAAV genomes can impact any of these crucial
aspects of SMRT library preparation and sequencing, requires careful
exploration. Lastly, the current format for AAV-GPseq unfortunately
cannot be applied directly to ssAAV genomes, since the ssAAV
genome on its own cannot serve as a self-complementary double-
stranded template for SMRT sequencing. However, it should be noted
that the current scAAV platforms exhibit several advantages—among
the most signiﬁcant are their higher stabilities upon transduction of
in vivo tissues, and their ability to bypass the rate-limiting step of sin-
gle-strand to double-strand conversion.10 Owing to these beneﬁts,
strategies using scAAVs are currently undergoing promising clinical
trials, which range from gene replacement therapies for hemophilia B
and spinal muscular dystrophy (SMA),24,25 to the more than 20
siRNA approaches for targeting disease-related genes.26 Therefore,
AAV-GPseq’s ability to speciﬁcally proﬁle scAAV genomes provides
a much-needed means for quality assessment for these potentially
powerful therapies. Further development of the AAV-GPseq work-
ﬂow to include methods for direct adaptering of single-stranded vec-
tor genomes is underway and will ensure that all clinical rAAVs are
safe and efﬁcacious for treating human diseases.
MATERIALS AND METHODS
Vector Constructs
The pscAAV-CB-EGFP, pAAVsc-CB6-PI-siFFLuc-inverted-EGFP,
and pH1-shApob-R constructs used in this study are described else-
where.7 All vectors were generated, puriﬁed, and titrated as described
previously.1 Puriﬁed viral vectors were digested with DNaseI, and
viral DNAs were extracted following procedures for extraction of re-
combinant adenovirus genomic DNA.1 Vector DNAs were subjected
to standard agarose electrophoresis, 2% agarose (Fisher Scientiﬁc,
Waltham, MA) in 0.5 Tris-Borate-EDTA (TBE) (Fisher) and EtBr
staining (Fisher). Fragment analysis of puriﬁed vector genomes by
capillary electrophoresis was performed by The Deep Sequencing
Core Facility at University of Massachusetts Medical School
(Worcester, MA).
SMRT Sequencing and Data Analysis
Viral DNA library preparation and sequencing were performed as
described previously with slight modiﬁcations.7 DNA from puriﬁed
rAAV preparations was spiked with 10% lDNA digested by BstEII
(NEB, Ipswich) for normalization. DNAs were subjected to DNA
nick and end repair, followed by direct ligation to SMRTbell adapters
at a 1:1 adaptor-to-vector molecular ratio, 1.8 AMPurePB bead pu-
riﬁcation, and sequenced on a Paciﬁc Biosciences RSII Instrument
running the SMRT Analysis v2.3 software packages at the Deep
Sequencing Core Facility at University of Massachusetts Medical
School. Of note, the standard PacBio SMRTbell library construction
efﬁciency for linear double-stranded DNA fragments is 30%–
36%, depending on the size of insert. For the libraries constructed
on scAAV genomes, the overall ligation efﬁciency was 14%–17%,
approximately 49.0%–56.6% of standard libraries. To ensure
maximum output of reads to deﬁne high-quality consensus reads,
6-hr movies were performed. Since our self-complementary genomes
have SMRTbell adapters at only one end of the molecule versus con-
ventional SMRTbell libraries with two, each molecule upon strand-
displacement sequencing will only generate forward reads separated
by the SMRTbell adaptor sequence instead of alternating forward
and reverse reads separated by the adapters. Therefore, to read these
speciﬁc libraries, the circular consensus algorithm in SMRT Analysis
2.3 is not acceptable. Instead, we employed the CCS2 algorithm
that performs a single-molecule consensus of reads regardless of
strandedness (i.e., it does not force a plus or minus strand to each
read pair and will align each read independent of strand orientation)
(N.L. Hepler, et al., 2016, Adv. Genome Biol. Technol., conference).
The following parameters were used: --minSnr=3.75 --minPasses=2
--minZScore=-10. The modiﬁed bam output ﬁle was converted to
fastq format for downstream analysis using bam2fastq, a component
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of SMRT Link v3.0. Reads were de-multiplexed and aligned to custom
reference sequences as described in Results using BWA-MEM on the
Galaxy web-based platform for genome data analysis.27–29 Data
was visualized using Integrative Genomes Viewer (IGV) version
2.3.61.19 Alignments to the human genome (hg38), are displayed as
tracks on the University of California Santa Cruz (UCSC) Genome
Browser.30,31 It should be noted that since scAAV-siFFLuc and
scAAV-shAboB-R vectors contain human sequences (U6 and H1
promoters, respectively), sequences mapping to these regions were
removed from the analysis. Circos plots were also employed to visu-
alize aligned reads.32 Venn diagrams were drawn using eulerAPE.33
Secondary structures of selected reads were visualized by mfold.34
Constraints to force base-pairing of ITR regions were used. Other pa-
rameters were set to default. Aggregation plots were generated using
ngs.plot (version 2.41).35
Read Count Normalization
To distinguish reads associated with the lDNA spike-in versus the
vector genome DNA pool, reads were simply mapped to either the
l-phage genome or the respective vector genome sequence. To deter-
mine the relative abundances of genomes in libraries, reads that
aligned to the Lambda phage reference were tabulated by size. A para-
bolic-spline of the lDNA was deﬁned by the count distribution of the
read lengths using the R package, smooth.spline(). The raw read
abundances of vector genomes of different sizes were ﬁtted to
lDNA deﬁned parabolic-spline.
Data Reporting
The datasets generated during and/or analyzed during the current
study are available in the NCBI Sequence Read Archive (SRA) under
the SubmissionID: SUB2583306, BioProject: PRJNA383145.
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